Although the phase II clinical trial in a KRAS-mutant non-small cell lung cancer (NSCLC) cohort showed promising efficacy, this activity was not confirmed in a phase III randomised study [33,34]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.